• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$4.32 -$0.02 (-0.46%)

REAL-TIME: Last trade at

Sequenom, Inc.

NASDAQ:SQNM

Leerinks' life science tools and medical devices analysts hold a conference call

AM Best Affirms Coventry's Ratings - Analyst Blog

AM Best Affirms Coventry's Ratings

Auriga Securities on Sequenom (SQNM): Coventry (CVH) Giveth, Coventry Taketh Away

Sequenom sinks after Coventry Health decides not to cover tests

Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21 PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets

Sequenom falls 7.6%

Sequenom gaps down, support is at $4.20, top of a prior bullish gap

Sequenom remains Overweight rated at Piper Jaffray

Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets

Salesforce.com: After-Hours Headlines

After-Hours Movers 05/17: (PSUN) (OSIR) (CRM) (BSX) Higher; (SQNM) (ARUN) (SIRI) Lower

Sequenom's Management Presents at Bank of America Merrill Lynch 2012 Healthcare Conference (Transcript)

Will Mayo v. Prometheus Fire Up Pharma?: Kevin DeGeeter

Blood-based Prenatal Test Maker Ariosa Diagnostics Gets Boost From Partnership With LabCorp

Sequenom Announces Coverage Agreement With Coventry Health Care For Sequenom Center For Molecular Medicine's MaterniT21™ PLUS Lab-Developed Test

Sequenom (SQNM) to Provide Coverage for Sequenom CMM MaterniT21 PLUS LDT

Sequenom announces coverage agreement with Coventry Health Care

Sequenom Announces Coverage Agreement With Coventry Health Care For Sequenom Center For Molecular Medicine's MaterniT21™ PLUS Lab-Developed Test

SAC Capital reports 5.4% passive stake in Sequenom

SAC Capital Raises Stake in Sequenom, Inc. (SQNM) to 5.35%

Sequenom should still hit targets despite Arisoa deal, says William Blair

Sequenom's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Sequenom reports Q1 EPS (22c), consensus (19c)

Sequenom, Inc. (SQNM) Misses Q1 EPS by 3c

Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic Cancer

Bullish Brokerage Attention Lures Call Players to Sequenom

Bullish Brokerage Attention Lures Call Players to Sequenom

Wedbush Upgrades Sequenom (SQNM) to Neutral; Limited Near-Term Negative Catalysts

Sequenom MaterniT21 volumes could top estimates in Q2, says William Blair

Sequenom upgraded to Neutral from Underperform at Wedbush

Sequenom Announces National Agreement With Provider MultiPlan, Inc.

Three Awesome Penny Stocks Breaking Out - Sequenom Inc., Anthera Pharmaceuticals Inc., Good Times Restaurants Inc.

Sequenom (SQNM) Enters Expanded Agreement with MultiPlan to Include MaterniT21 PLUS Test

Sequenom announces national agreement with provider Multiplan

Sequenom Announces National Agreement with Provider MultiPlan, Inc.

Sequenom Sales Exceed Expectations

Sequenom (SQNM) Enters Term Supply Agreement Amendment with Illumina (ILMN)

Sequenom Announces Amendment to Multi-Year Supply Agreement with Illumina

Sequenom announces amendment to multi-year agreement with Illumina

See More Articles...